MASI - Masimo Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
123.58
+1.11 (+0.91%)
At close: 4:00PM EDT

123.58 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close122.47
Open121.97
Bid123.52 x 800
Ask123.59 x 1300
Day's Range118.93 - 124.99
52 Week Range88.09 - 141.05
Volume495,747
Avg. Volume426,459
Market Cap6.594B
Beta (3Y Monthly)1.43
PE Ratio (TTM)35.82
EPS (TTM)3.45
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-11-23
1y Target Est150.40
Trade prices are not sourced from all markets
  • Hedge Funds Have Never Been More Bullish On Masimo Corporation (MASI)
    Insider Monkey12 hours ago

    Hedge Funds Have Never Been More Bullish On Masimo Corporation (MASI)

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth […]

  • Business Wire14 hours ago

    Masimo to Report First Quarter 2019 Financial Results after Market Close on Monday, May 6

    Conference call and webcast to begin at 1:30 p.m. PT

  • Intuitive Surgical (ISRG) Q1 Earnings, Revenues Lag Estimates
    Zacks14 hours ago

    Intuitive Surgical (ISRG) Q1 Earnings, Revenues Lag Estimates

    Intuitive Surgical's (ISRG) Q1 results outside the United States impress.

  • Dow Jones Falls As Medical Stocks Massacred, But Top Stocks Thrive In These Sectors
    Investor's Business Daily5 days ago

    Dow Jones Falls As Medical Stocks Massacred, But Top Stocks Thrive In These Sectors

    Amid dull moves by the Dow Jones Industrial Average and S&P 500, drops by medical stocks were hardly small. Many health care stocks hit sell signals.

  • Stryker's LIFEPAK CR2 Defibrillator Launch to Boost MedSurg
    Zacks6 days ago

    Stryker's LIFEPAK CR2 Defibrillator Launch to Boost MedSurg

    Stryker's (SYK) emergency care department offers a broad range of products and systems.

  • Here's Why You Should Buy Masimo (MASI) Stock Right Now
    Zacks6 days ago

    Here's Why You Should Buy Masimo (MASI) Stock Right Now

    Masimo (MASI) has been benefitting from developments like the FDA clearance of the Rad-67 Pulse CO-Oximeter.

  • New Study Investigates Cerebral Oxygenation Normative Values Using Masimo O3® Regional Oximetry
    Business Wire8 days ago

    New Study Investigates Cerebral Oxygenation Normative Values Using Masimo O3® Regional Oximetry

    Masimo  announced today the findings of a study, recently published in Anaesthesia and Intensive Care, in which researchers at Austin Hospital in Melbourne, Australia sought to measure cerebral oxygenation in a large cohort of healthy volunteers, using Masimo O3® Regional Oximetry, to establish a normal range of values and investigate the relationship between cerebral oxygenation and other physical ...

  • Here's Why Investors Should Retain Accuray (ARAY) Stock Now
    Zacks12 days ago

    Here's Why Investors Should Retain Accuray (ARAY) Stock Now

    Management at Accuray (ARAY) sees significant opportunities in China.

  • Here's Why You Should Buy Varian Medical (VAR) Stock Now
    Zacks13 days ago

    Here's Why You Should Buy Varian Medical (VAR) Stock Now

    Varian Medical (VAR) announces the installation of cyclotron for its ProBeam proton therapy system at the Hefei Ion Medical Center in China.

  • Align Rides on Firm Global Footprint Despite Fierce Rivalry
    Zacks13 days ago

    Align Rides on Firm Global Footprint Despite Fierce Rivalry

    Align's (ALGN) solid performance in the Europe, Middle East and Africa and Asia-Pacific geographies is appreciative.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Masimo Corp.

    Masimo Corp NASDAQ/NGS:MASIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for MASI with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MASI. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MASI are favorable with net inflows of $72.91 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Masimo Corporation (NASDAQ:MASI): What Can We Expect In The Future?
    Simply Wall St.15 days ago

    Masimo Corporation (NASDAQ:MASI): What Can We Expect In The Future?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Since Masimo Corporation (NASDAQ:MASI) released its earnings in December 2018...

  • Here's Why You Should Hold Becton, Dickinson Stock for Now
    Zacks18 days ago

    Here's Why You Should Hold Becton, Dickinson Stock for Now

    Becton, Dickinson (BDX) announces the FDA premarket approval for Venovo venous stent device.

  • ABIOMED Impella Data Show Significant Rise in Survival Rates
    Zacks18 days ago

    ABIOMED Impella Data Show Significant Rise in Survival Rates

    ABIOMED (ABMD) plans to expand products like Impella CP, Impella Connect, Impella 5.5 and Impella RP.

  • 7 A-Rated Healthcare Stocks for Industry Expansion
    InvestorPlace18 days ago

    7 A-Rated Healthcare Stocks for Industry Expansion

    According to the Centers for Medicare and Medicaid Services, healthcare spending in 2017 represented nearly 18% of U.S. GDP that year. And it projected that spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP -- a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 Biometric Stocks to Watch as AI Rises That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets. Healthcare Stocks: Masimo (MASI)Source: FlickrMasimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 59% in the past 12 months, and half of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like. Ionis Pharmaceuticals (IONS)Source: Shutterstock Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on.This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments. * The Elite 8 Stocks to Buy for Massive Outperformance IONS is already partnered with a number of larger pharmaceutical firms and is up 94% in the past year, with plenty of headroom left. Osiris Therapeutics (OSIR)Source: Shutterstock Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 118% for the year and 46% in 2019. Ensign Group (ENSG)Source: Shutterstock Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles.It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is. * 10 Tech Stocks That Transformed Their Business Up 94% in the past year, its size makes it a potential takeover target or a big grower on its own. Genomic Health (GHDX)Source: Shutterstock Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 112% in the past year and it's still going strong. National Research Corp (NRC)Source: Shutterstock National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research.While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos Up 30% in the past year, NRC also delivers a near-2% dividend. AngioDynamics (ANGO)Source: Flickr>AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Up almost 20% in the past year, the future is bright. And its global potential is huge, as China looks to upgrade its entire healthcare system.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.

  • Varian Medical Opens Office in South Africa, Expands in EMEA
    Zacks19 days ago

    Varian Medical Opens Office in South Africa, Expands in EMEA

    Varian Medical (VAR) sees a slew of developments in the EMEA region of late.

  • Business Wire21 days ago

    Masimo to Present at 18th Annual Needham Healthcare Conference

    Masimo today announced that its management is scheduled to present at the 18th Annual Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 9, 2019 at 12:50 p.m.

  • Here's Why You Should Retain ABIOMED Stock in Your Portfolio
    Zacks21 days ago

    Here's Why You Should Retain ABIOMED Stock in Your Portfolio

    Despite cutthroat competition in the niche markets, ABIOMED (ABMD) seems to be well-positioned for growth on strong guidance and solid product portfolio.

  • Integer Holdings Gets Positive Outlook & B+ Rating From S&P
    Zacks21 days ago

    Integer Holdings Gets Positive Outlook & B+ Rating From S&P

    Integer (ITGR) strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.

  • Why Is Masimo (MASI) Up 2.5% Since Last Earnings Report?
    Zacks26 days ago

    Why Is Masimo (MASI) Up 2.5% Since Last Earnings Report?

    Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Allscripts' FollowMyHealth Partners Ephraim McDowell Health
    Zacks27 days ago

    Allscripts' FollowMyHealth Partners Ephraim McDowell Health

    Allscripts' (MDRX) FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians.

  • Fresenius Medical to Make Huge Investments, Competition Rife
    Zacks27 days ago

    Fresenius Medical to Make Huge Investments, Competition Rife

    Fresenius Medical (FMS) is likely to make huge investments in India and China.

  • Masimo Gets FDA Clearance for Rad-67 Monitoring Device
    Zacks28 days ago

    Masimo Gets FDA Clearance for Rad-67 Monitoring Device

    The clearance will enable Masimo (MASI) to provide portable spot-checking monitoring measurements of oxygen saturation and non-invasive hemoglobin.

  • Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip
    Zacks28 days ago

    Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip

    On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.